Innovative Approximate Analytical Solution for Standard Model of Viral Dynamics: Hepatitis C with Direct-Acting Agents as an Implemented Case

In this article, a novel approximate analytical solution is presented for solving the standard viral dynamic model. Basically, the standard model is used to study viral dynamics in patients for a wide range of viruses like HIV, HPV, HBV, and HCV. In this research work, the standard model for hepatitis C virus (HCV) is considered in detail; however, the analysis and results can be applicable for all other viruses. This standard model is used to study viral dynamics in patients treated with direct-acting antiviral agents (DAAs). Power series solution combined with Laplace–Pade resummation method (PSLP) is used to obtain the approximate analytical solutions for the model. To test the capability as well as the validity of the proposed method, results are compared with available viral load data published in the literature and with published simulation results. Good fits are obtained in the comparison for all cases considered. Given that medical specialists and physicians are more interested in solutions that yield direct and simple predictions, it is expected that the proposed approximate analytical solution would be attractive to them and help them to obtain a straightforward and a proper estimation regarding the viral load due to variations in treatment and/or patient’s parameters.

[1]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[2]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[3]  H. Elkaranshawy,et al.  Modified Parker-Sochacki method for solving nonlinear oscillators , 2017 .

[4]  William M. Lee,et al.  Interferon Alfa-2 b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C , 2015 .

[5]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[6]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[7]  M A Nowak,et al.  The dynamics of hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Neumann,et al.  Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. , 2010, Journal of theoretical biology.

[9]  H. Vázquez-Leal,et al.  Application of series method with Padé and Laplace-Padé resummation methods to solve a model for the evolution of smoking habit in Spain , 2014 .

[10]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[11]  D. S. Jones,et al.  Differential Equations and Mathematical Biology , 1983 .

[12]  Yanni Xiao,et al.  Global Dynamics of a Virus-Immune System with Virus-Guided Therapy and Saturation Growth of Virus , 2018, Mathematical Problems in Engineering.

[13]  Alan S. Perelson,et al.  Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model , 2013, PLoS Comput. Biol..

[14]  Thi Huyen Tram Nguyen,et al.  Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens , 2017, PloS one.

[15]  Wen-Hsien Ho,et al.  Hybrid Taguchi-Differential Evolution Algorithm for Parameter Estimation of Differential Equation Models with Application to HIV Dynamics , 2011 .

[16]  H. Elkaranshawy,et al.  Power Series Solution to Sliding Velocity in Three-Dimensional Multibody Systems with Impact and Friction , 2015 .

[17]  Martin A Nowak,et al.  Mathematical models of HIV pathogenesis and treatment. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[18]  G. A. Baker,et al.  Padé Approximants Second Edition: Extensions of Padé approximants , 1996 .

[19]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[20]  T. Ayer,et al.  Hepatitis C virus re‐treatment in the era of direct‐acting antivirals: projections in the USA , 2018, Alimentary pharmacology & therapeutics.

[21]  S. Lenhart,et al.  The Dynamics of HPV Infection and Cervical Cancer Cells , 2015, Bulletin of Mathematical Biology.

[22]  H. Elkaranshawy,et al.  Extended Parker-Sochacki method for Michaelis-Menten enzymatic reaction model. , 2016, Analytical biochemistry.

[23]  Libin Rong,et al.  Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.

[24]  Libin Rong,et al.  Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. , 2013, Mathematical biosciences.

[25]  Danna Zhou,et al.  d. , 1934, Microbial pathogenesis.

[26]  L. Henry,et al.  Sofosbuvir (Sovaldi) for the treatment of hepatitis C , 2014, Expert review of clinical pharmacology.

[27]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[29]  Ahmet Yildirim,et al.  Series solution of a nonlinear ODE arising in magnetohydrodynamic by HPM-Padé technique , 2011, Comput. Math. Appl..

[30]  Alan S. Perelson,et al.  Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and Interleukin-28B , 2011 .

[31]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[32]  Anushree Chatterjee,et al.  Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? , 2012, Antiviral therapy.

[33]  Patrick Levoir,et al.  Direct analysis of chemical relaxation signals by a method based on the combination of Laplace transform and Padé approximants , 1987, Comput. Chem..

[34]  T. Asselah,et al.  New direct‐acting antivirals' combination for the treatment of chronic hepatitis C , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[35]  Thi Huyen Tram Nguyen,et al.  The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? , 2017, Scientific Reports.

[36]  S. Effati,et al.  Multiobjective Optimal Control of HIV Dynamics , 2010 .

[37]  Lequan Min,et al.  Mathematical Analysis of a Basic Virus Infection Model With Application to HBV Infection , 2008 .